- Home
- PMEC vs APRE Comparison
PMEC vs APRE Comparison
Compare PMEC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- APRE
- Stock Information
- Founded
- PMEC 1984
- APRE 2006
- Country
- PMEC Singapore
- APRE United States
- Employees
- PMEC N/A
- APRE N/A
- Industry
- PMEC
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMEC
- APRE Health Care
- Exchange
- PMEC Nasdaq
- APRE Nasdaq
- Market Cap
- PMEC 23.4M
- APRE 20.2M
- IPO Year
- PMEC 2023
- APRE 2019
- Fundamental
- Price
- PMEC $0.61
- APRE $3.25
- Analyst Decision
- PMEC
- APRE Strong Buy
- Analyst Count
- PMEC 0
- APRE 2
- Target Price
- PMEC N/A
- APRE $15.50
- AVG Volume (30 Days)
- PMEC 64.4K
- APRE 5.9K
- Earning Date
- PMEC 09-26-2024
- APRE 11-07-2024
- Dividend Yield
- PMEC N/A
- APRE N/A
- EPS Growth
- PMEC N/A
- APRE N/A
- EPS
- PMEC N/A
- APRE N/A
- Revenue
- PMEC $72,524,000.00
- APRE $1,275,686.00
- Revenue This Year
- PMEC N/A
- APRE $96.15
- Revenue Next Year
- PMEC N/A
- APRE N/A
- P/E Ratio
- PMEC N/A
- APRE N/A
- Revenue Growth
- PMEC 5.07
- APRE 410.91
- 52 Week Low
- PMEC $0.49
- APRE $2.99
- 52 Week High
- PMEC $4.18
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- PMEC 53.28
- APRE 43.65
- Support Level
- PMEC $0.58
- APRE $3.10
- Resistance Level
- PMEC $0.66
- APRE $3.50
- Average True Range (ATR)
- PMEC 0.05
- APRE 0.19
- MACD
- PMEC 0.00
- APRE 0.00
- Stochastic Oscillator
- PMEC 55.22
- APRE 46.43
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).